UNSPSC 51382700: Nonsteroidal anti inflammatory indenes

Nonsteroidal anti inflammatory drugs made from Nonsteroidal anti inflammatory drugs made from a family of fused-ring hydrocarbons isolated from coal tar that act as intermediates in various chemical reactions and are used in the production of coumarone-indene resins.

UNSPSC 51382700 Nonsteroidal anti inflammatory indenes is a Class code that in practice spans pharmaceutical procurement across multiple product categories — the recent state and local activity under this code includes naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products. State and local governments buying under this code range from county health departments to state health and human services agencies, with cooperative purchasing alliances (such as Minnesota's MMCAP) playing a significant role in aggregating demand across multiple jurisdictions. The scope of work involves commodity purchasing of finished pharmaceutical products through competitive bidding, with vendors required to meet FDA compliance, cGMP certification, Drug Supply Chain Security Act (DSCSA) adherence, and insurance requirements including workers' compensation and commercial general liability coverage.

Recent activity spans Florida, Texas, and the Upper Midwest. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, seeking information on vendor experience with direct contracting models outside traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration's MMCAP issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026, evaluating vendors on fixed pricing (10 percent), administrative compliance (5 percent), EDI capability (5 percent), fee acceptance (5 percent), and price competitiveness (75 percent), with a two-year initial term effective July 1, 2026.